Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Inside the big push to get enough H1N1 vaccines, with CNBC's Mike Huckman.
Wayne Pisano, CEO of Sanofi-Pasteur, discusses the making of the flu vaccine with CNBC's Mike Huckman.
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 07:49:20 10 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 07:49:20 10 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/10/2009 7:51:08 AM

RSS FEED

» Help

Current DateTime: 07:49:24 10 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size

Ads for flu vaccines have traditionally been confined to public service announcements (PSAs), health and media alerts.

So, that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune.

Flumist Advertisement
NY Times
Flumist Advertisement

FluMist, as its name might suggest, is the vaccine that gets sprayed in your nose. MedImmune developed the product and brought it to market. But by industry standards, it's been a mediocre seller: For example, during the last flu season, FluMist had $55 million in revenue. That's a drop in the bucket for AstraZeneca [AZN  Loading...      ()   ].

That's probably why AZN, which bought MedImmune but let the company keep its name, is trying to put some big pharma marketing muscle behind FluMist. It's just kinda strange to see a big ad for a flu vaccine, especially in the middle of summer -- although I assume it's designed to blend in with and capitalize on the back-to-school shopping season stuff.

The companies recently announced that they started shipping around 12 million doses for the upcoming season, and that FluMist will be available in more locations than ever before. A FluMist spokesperson says this is a limited-time print-ad campaign that started running in the The Wall Street Journal and the Times within the past couple weeks.

MedImmune is one of the biopharma companies that billionaire activist investor Carl Icahn took a stake in, and saw it through to a very lucrative takeover by AZN.

This weekend Barron's ran a piece regarding something I've been reporting on and blogging about for quite some time: big pharma's continuing thirst for biotech. The article mentions Icahn's ImClone Systems [IMCL  Loading...      ()   ] and the "uncertain" outcome of Bristol-Myers Squibb's [BMY  Loading...      ()   ] offer for IMCL.

The story also ticks off the short-list of potential biotech takeover targets, including another one of Icahn's new babies: Amylin Pharmaceuticals [AMLN  Loading...      ()   ].

The story couldn't save Amylin shares from dropping more than 8 percent Monday, however, on reports that the FDA is seeking stronger warnings about the risk of pancreatitis in patients taking the firm's injectable diabetes drug Byetta.

In a note to subscribers today, David Kliff, editor of "The Diabetic Investor" newsletter, points out that Icahn recently increased his stake in AMLN from 6.3 million to 6.8 million shares.

Kliff says, "Carl sees the path for Amylin and has the clout to hit Lilly [LLY  Loading...      ()   ] (AMLN's diabetes drug partner)...with a baseball bat pushing Lilly to acquire Amylin."

For the record, LLY and AMLN officials have consistently said they're happy with the partnership as it is. But while Kliff praises Icahn for his AMLN strategy, he also expresses incredulity about Icahn's new stake in another diabetes player, Emisphere [EMIS  Loading...      ()   ]. Diabetes drug goliath Novo Nordisk [NVO  Loading...      ()   ] recently did a deal with EMIS to develop an oral treatment for the disease.

Kliff is skeptical about the drug's prospects, to say the least. "Even billionaires can make a mistake," he writes. I wouldn't know.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 06:23:05 10 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:20 10 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 06:22:21 10 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:06:21 10 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters